Evidence map›Paper›PMID 36909561›Full record

ArticlebioRxiv : the preprint server for biology2023

Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations.

Hong Yan, Ronan Talty, Abhishek Jain, Yuping Cai, Jie Zheng, Xinyi Shen, Engjel Muca, Philip B Paty, Marcus W Bosenberg, Sajid A Khan and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Hong YanDepartment of Environmental Health Sciences, Yale School of Public Health, Yale University, USA.
Ronan TaltyDepartment of Pathology, Yale School of Medicine, USA.
Abhishek JainDepartment of Environmental Health Sciences, Yale School of Public Health, Yale University, USA.
Yuping CaiDepartment of Environmental Health Sciences, Yale School of Public Health, Yale University, USA.
Jie ZhengDepartment of Environmental Health Sciences, Yale School of Public Health, Yale University, USA.
Xinyi ShenDepartment of Environmental Health Sciences, Yale School of Public Health, Yale University, USA.
Engjel MucaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, USA.
Philip B PatyDepartment of Surgery, Memorial Sloan Kettering Cancer Center, USA.
Marcus W BosenbergDepartments of Pathology, Dermatology, and Immunobiology, Yale School of Medicine, USA.
Sajid A KhanDivision of Surgical Oncology, Department of Surgery, Yale School of Medicine, USA.
Caroline H JohnsonDepartment of Environmental Health Sciences, Yale School of Public Health, Yale University, USA.
Yale University · USMemorial Sloan Kettering Cancer Center · USChinese Academy of Sciences · CN

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI MARCUS W BOSENBERG, Harriet M. Kluger · 2006 to 2026
$43.9M
YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAMK12CA215110 · NCI · YALE UNIVERSITY · PI Harriet M. Kluger · 2018 to 2026
$6.1M
Understanding sex differences in colon cancer metabolismR21CA223686 · NCI · YALE UNIVERSITY · PI JOHNSON, CAROLINE HELEN, KHAN, SAJID A · 2018 to 2019
$394k
Ferroptosis as a Modulator of Checkpoint Inhibitor ImmunotherapyF30CA254246 · NCI · YALE UNIVERSITY · PI TALTY, RONAN CHRISTOPHER · 2021 to 2023
$95k
NCATS NIH HHS UL1 TR001863NCI NIH HHS F30 CA254246NCI NIH HHS K12 CA215110NCI NIH HHS P50 CA121974NCI NIH HHS R21 CA223686
6 · The paper itself

Abstract

Aberrant tumor metabolism is a hallmark of cancer in which metabolic rewiring can support tumor growth under nutrient deficient conditions. KRAS mutations occur in 35-45% of all colorectal cancer (CRC) cases and are difficult to treat. The relationship between mutant KRAS and aberrant metabolism in CRCs has not been fully explored and could be a target for intervention. We previously acquired non-targeted metabolomics data from 161 tumor tissues and 39 normal colon tissues from stage I-III chemotherapy naïve CRC patients. In this study, we revealed that tumors from male patients with KRAS mutations only, had several altered pathways that suppress ferroptosis, including glutathione biosynthesis, transsulfuration activity, and methionine metabolism. To validate this phenotype, MC38 CRC cells (KRAS

Identifiers

PMID36909561
PMCPMC10002683
OpenAlexW4323038264

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.